The Epigenetic Landscape in the Treatment of Gynecologic Malignancies

Area of Science:

• Gynecologic Oncology
• Cancer Epigenetics
• Molecular Oncology

Background:

• Advanced-stage or recurrent endometrial, ovarian, and cervical cancers present significant clinical challenges.
• Survival outcomes for these gynecologic cancers have seen minimal improvement despite advances in therapeutics and supportive care.
• Genomic alterations and the tumor microenvironment are known contributors to cancer progression.

Purpose of the Study:

• To review the epigenetic landscape of endometrial, ovarian, and cervical cancers.
• To describe the current state of scientific understanding regarding epigenetic contributions to gynecologic cancers.
• To discuss potential clinical applications of targeting epigenetic mechanisms.

Main Methods:

• Review of current scientific literature on gynecologic cancer epigenetics.
• Analysis of established genomic alterations and tumor microenvironment factors.
• Exploration of epigenetic mechanisms including DNA methylation, histone modification, and noncoding RNA expression.

Main Results:

• Epigenetic mechanisms, including DNA methylation, histone modification, and noncoding RNA expression, are increasingly recognized as critical in gynecologic cancer initiation and progression.
• These epigenetic alterations represent promising novel therapeutic targets.
• The precise role and clinical efficacy of epigenetic drugs in treating gynecologic cancers are still under investigation.

Conclusions:

• Epigenetic modifications play a significant role in the progression of endometrial, ovarian, and cervical cancers.
• Targeting epigenetic mechanisms presents a potential avenue for future gynecologic cancer treatments.
• Further research is needed to clarify the role of epigenetic drugs in clinical practice for these cancers.